International Journal of Clinical Oncology

, Volume 16, Issue 2, pp 153–155 | Cite as

Metastatic collecting duct carcinoma of the kidney responded to sunitinib

  • Hideaki Miyake
  • Takahiro Haraguchi
  • Atsushi Takenaka
  • Masato Fujisawa
Case Report


Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive malignant tumor arising from the distal collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor, sunitinib, achieving a partial response in both lung and skeletal metastases. To our knowledge, this is the first report showing therapeutic activity of sunitinib against CDC. Considering these findings, it would be worthwhile prospectively investigating the role of multiple tyrosine kinase inhibitors, particularly sunitinib, in the management of metastatic CDC.


Collecting duct carcinoma Sunitinib Metastasis 


Conflict of interest



  1. 1.
    Srigley JR, Eble JN (1998) Collecting duct carcinoma of kidney. Semin Diagn Pathol 15:54–67PubMedGoogle Scholar
  2. 2.
    Gollob JA, Upton MP, DeWolf WC et al (2001) Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology 58:1058PubMedCrossRefGoogle Scholar
  3. 3.
    Milowsky MI, Rosmarin A, Tickoo SK et al (2002) Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer 94:111–116PubMedCrossRefGoogle Scholar
  4. 4.
    Peyromaure M, Thiounn N, Scotté F et al (2003) Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. J Urol 170:1138–1140PubMedCrossRefGoogle Scholar
  5. 5.
    Tokuda N, Naito S, Matsuzaki O et al (2006) Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol 176:40–43PubMedCrossRefGoogle Scholar
  6. 6.
    Oudard S, Banu E, Vieillefond A et al (2007) Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) study. J Urol 177:1698–1702PubMedCrossRefGoogle Scholar
  7. 7.
    Chao D, Zisman A, Pantuck AJ (2002) Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol 167:71–74PubMedCrossRefGoogle Scholar
  8. 8.
    Rini BI, Flaherty K (2008) Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol Oncol 26:543–549PubMedGoogle Scholar
  9. 9.
    Choueiri TK, Plantade A, Elson P et al (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26:127–131PubMedCrossRefGoogle Scholar
  10. 10.
    Ansari J, Fatima A, Chaudhri S et al (2009) Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. Onkologie 32:44–46PubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2010

Authors and Affiliations

  • Hideaki Miyake
    • 1
  • Takahiro Haraguchi
    • 1
  • Atsushi Takenaka
    • 1
  • Masato Fujisawa
    • 1
  1. 1.Division of UrologyKobe University Graduate School of MedicineKobeJapan

Personalised recommendations